Google dives into life sciences; Biotronik launches ablation catheter;

@FierceMedDev: Doctors may be overusing MRI facilities they own. More from FierceDiagnostics | Follow @FierceMedDev

@DamianFierce: Covidien plots job cuts, plant closures to save $300M. News | Follow @DamianFierce

@MarkHFierce: Agilent will split in two, keeping its growing Dx business under the current name. Press release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an insulin pump with a continuous glucose monitor. Who will get one to market first? Feature from FierceDrugDelivery | Follow @MichaelGFierce

> Google ($GOOG) is trying its hand at life sciences, hiring well-regarded Genentech chairman Art Levinson to run its newly created Calico offshoot. Article

> Exosome Diagnostics has signed a deal with Eli Lilly ($LLY) to help the drugmaker find and validate biomarkers that predict drug response. News

> Covidien's ($COV) board of directors voted to boost the quarterly dividend rate by 23%, reflecting the company's solid performance so far in 2013. Item

> Germany's Biotronik has launched its AlCath Flutter Gold ablation catheter in Europe, looking to capitalize on the market for atrial flutter treatments. Release

> Patients implanted with everolimus-eluting stents had lower rates of adverse events than those who got paclitaxel-eluting devices, according to a study. More

> Colorado's Crosstrees Medical gained the FDA's 510(k) clearance for its PVA Pod System, which is designed to help physicians control the flow of bone cement during vertebral fracture repair procedures. Item

Biotech News

@FierceBiotech: Popular yesterday from FierceBiomarkers: 12-year study flags new biomarker for high risk of diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Google is making waves in biotech, glad Google Ventures' Krishna Yeshwant is speaking at our Oct. 15 event in Boston. Register here | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Stem cell therapy protects vision in preclinical retinal disease study. More from FierceBiotech Research | Follow @EmilyMFierce

> Acceleron raises $93M as Celgene, investors rally around another biotech IPO. Report

> BioMarin spike fades as Roche CEO guns down latest takeover rumor. Story

> Wearing biotech hat, hedge fund vet Shkreli shakes the gate at Transcept. More

> Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article

Pharma News

@FiercePharma: Still trending on our website: FDA turbocharges Glaxo's bids for new cancer drug uses. Article | Follow @FiercePharma

@CarlyHFierce: Gold-encrusted mooncakes stuffed with shark's fin "out of favor" in China; corruption crackdown has killed demand. More from Reuters | Follow @CarlyHFierce

> Roche chief tamps down talk of $13.5B BioMarin buyout. Story

> Sanofi CEO: Thanks to Genzyme, investors take us seriously. Report

Vaccines News

> Study links delayed vaccines to increased risk of whooping cough. More

> Unvaccinated clusters bear brunt of bad year for measles in U.S. Story

> Brain cancer vaccine data gives Agenus' stock a boost. Article

> India gives 114 kids the wrong vaccine in polio mix-up. News

> NIH trialing Sanofi H7N9 vaccine with GSK, Novartis adjuvants. Report

> Visterra advances universal flu antibody to cusp of Phase I. Item

Pharma Manufacturing News

@EricPFierce: Bad luck for this Shamrock. FDA clobbers it with a consent decree and permanent injunction. More | Follow @EricPFierce

> Hikma, partner to build $20M plant in Ethiopia. Story

> FDA uncovers big foul-ups at Ranbaxy plant. Article

> Aesica invests $48M in U.K. plant to make diabetes drugs. News

> MIT works on process to manufacture biologics in 24 hours. Item

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.